The FDA has just issued a Breakthrough Device designation and an Investigational Device Exemption (IDE) to CSA Medical for its RejuvenAir system as a treatment option for patients with moderate to severe chronic obstructive pulmonary disease (COPD) that have chronic bronchitis. The company soon plans to start a prospective, multi-center, blinded (Read more...)